Dr. Mohammad Ali Kizilbash, MD

Dr. Kizilbash practices at Northwestern Medicine McHenry Hospital in Mchenry, Illinois, part of Northwestern Memorial HealthCare.

Dr. Kizilbash's NPI, 1114162948, was assigned on December 8, 2008. Dr. Kizilbash holds Illinois license 036-111516.

Dr. Kizilbash's primary practice is Northwestern Medicine McHenry Hospital, at 4201 Medical Center Drive, Mchenry, IL 60050 in Mc Henry County. The practice phone is (815) 344-5000.

Dr. Kizilbash's primary practice is Northwestern Medicine McHenry Hospital in Mchenry, Illinois, part of Northwestern Memorial HealthCare. Dr. Kizilbash is also affiliated with Northwestern Medicine Central DuPage Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Kizilbash to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kizilbash practices, 8 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Kizilbash's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Kizilbash's licenses on file in 2 states: Illinois and Missouri.

CMS data shows 7,344 Medicare services from Dr. Kizilbash across 30 procedure codes in 2024, for 3,043 Medicare patients. Medicare paid $293,783 for them.

CMS counts 3,043 Medicare patients who saw Dr. Kizilbash in 2024. The largest group is 75 to 84, with 1,216 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kizilbash's median patient age at 71, with 50% women.

In 2024, Dr. Kizilbash wrote 6,575 Medicare Part D claims for 1,259 patients. 88% of them were for generic drugs. CMS names the drug for 6,261 of them, across 49 drugs with 11 or more claims each, at $1,051,478 in total drug cost. In 2023, CMS named 5,702 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kizilbash for performance year 2024, reported through an alternative payment model (APM). Dr. Kizilbash accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kizilbash as offering telehealth.

Dmand AI links 6 papers to Dr. Kizilbash in 2011. 2011 was the busiest year, with 3. The most frequent topics are Randomized Controlled Trials as Topic. Dr. Kizilbash's most frequent co-authors are Luis C. Afonso, MD, Ankit Dineshbhai Rathod, MD and Sony Jacob, MD.

CMS Open Payments shows 93 general payments to Dr. Kizilbash from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. Edwards Lifesciences Corporation paid the most, $13,458.